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A proline-to-serine substitution at position 56 in the gene encoding vesicle-associated membrane protein-
associated protein B (VAPB; VAPBP56S) causes some dominantly inherited familial forms of motor neuron
disease, including amyotrophic lateral sclerosis (ALS) type-8. Here, we show that expression of ALS
mutant VAPBP56S but not wild-type VAPB in neurons selectively disrupts anterograde axonal transport of
mitochondria. VAPBP56S-induced disruption of mitochondrial transport involved reductions in the fre-
quency, velocity and persistence of anterograde mitochondrial movement. Anterograde axonal transport of
mitochondria is mediated by the microtubule-based molecular motor kinesin-1. Attachment of kinesin-1 to
mitochondria involves the outer mitochondrial membrane protein mitochondrial Rho GTPase-1 (Miro1)
which acts as a sensor for cytosolic calcium levels ([Ca
21]c); elevated [Ca
21]c disrupts mitochondrial trans-
port via an effect on Miro1. To gain insight into the mechanisms underlying the VAPBP56S effect on mito-
chondrial transport, we monitored [Ca
21]c levels in VAPBP56S-expressing neurons. Expression of
VAPBP56S but not VAPB increased resting [Ca
21]c and this was associated with a reduction in the amounts
of tubulin but not kinesin-1 that were associated with Miro1. Moreover, expression of a Ca
21 insensitive
mutant of Miro1 rescued defective mitochondrial axonal transport and restored the amounts of tubulin asso-
ciated with the Miro1/kinesin-1 complex to normal in VAPBP56S-expressing cells. Our results suggest that
ALS mutant VAPBP56S perturbs anterograde mitochondrial axonal transport by disrupting Ca
21 homeosta-
sis and effecting the Miro1/kinesin-1 interaction with tubulin.
INTRODUCTION
Axonal transport of mitochondria is essential for neuronal health
and survival since mitochondria need to distribute to axonal
regions where their functions in ATP synthesis and Ca
2+ buffer-
ing are needed the most. Compared with most cells, neurons
have high metabolic and Ca
2+-buffering requirements. Thus,
mitochondria are transported bi-directionally through axons
and this movement is responsive to physiological stimuli (1).
The microtubule-based motor kinesin-1 mediates most
anterograde transport of mitochondria (2–7). One route
whereby mitochondria attach to kinesin-1 involves Miro1 and
trafﬁcking kinesin protein-1 (TRAK1); Miro1 is an outer mito-
chondrial membrane protein and TRAK1 is an adaptor protein
that binds to both Miro1 and kinesin-1 (2,7–15). Increased
[Ca
2+]c halts mitochondrial transport and this involves Miro1
which contains two EF hands that bind Ca
2+ and enable it to
act as a Ca
2+ sensor (8,11,16–19).
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Advance Access published on January 17, 2012Defective axonal transport of mitochondria is seen in a
number of human motor neuron diseases (20–25). Amyo-
trophic lateral sclerosis (ALS) is the most common adult
onset form of motor neuron disease and some forms of
ALS are familial. A mutation in the gene encoding
vesicle-associated membrane protein-associated protein B
(VAPB) causes some dominantly inherited forms of motor
neuron disease, including ALS type-8 (26). VAPB is an inte-
gral endoplasmic reticulum (ER) protein and the ALS8 muta-
tion involves a proline-to-serine substitution at position-56
(VAPBP56S). VAPBP56S induces the formation of abnormal
ER-derived inclusions (26–31). The function of VAPB is not
properly understood; there is evidence that it has roles in ER
stress, ER to Golgi transport, bouton formation at the neuro-
muscular junction, Ca
2+ homeostasis and signaling via
ephrin receptors (29,32–40). Likewise, the precise mechanism
by which VAPBP56S induces disease is not known, although
several studies implicate a role for ER stress in this process
(41). Here, we show that VAPBP56S reduces anterograde
axonal transport of mitochondria and that this involves disrup-
tion to cellular Ca
2+ homeostasis.
RESULTS
VAPBP56S selectively disrupts anterograde axonal
transport of mitochondria
To investigate any effect of VAPB and VAPBP56S on axonal
transport of mitochondria, we quantiﬁed mitochondrial trans-
port through axons of living transfected rat cortical neurons
by time-lapse microscopy essentially as described in our pre-
vious studies (20). Neurons were co-transfected with DsRed-
Mito (to visualize mitochondria) and either control vector
(vector expressing enhanced green ﬂuorescent protein;
EGFP), EGFP-VAPB or EGFP-VAPBP56S. In line with our
previous work (42,43), we chose cells expressing low levels
of transfected proteins (as judged by brightness of EGFP
signal) for analyses to avoid any possible artifacts produced
by high-level expression. Several groups have now successful-
ly utilized EGFP tagging to study VAPB/VAPBP56S metabol-
ism (26,36,38,44,45).
We analyzed the overall transport of mitochondria from
kymographs by calculating the distance between the position
of individual mitochondria at the start and end of time-lapse
recordings and dividing by the time elapsed. This yielded
an average transport velocity for each mitochondrion that
includes anterograde and retrograde movements and stationary
periods. Mitochondria were classiﬁed as motile when their
velocity exceeded 0.1 mm/s or as stationary when their vel-
ocity was ≤0.1 mm/s. Quantiﬁcation of the overall transport
of mitochondria revealed that in control axons  38% of mito-
chondria were motile with  24 and 14% moving in antero-
grade and retrograde directions, respectively (Fig. 1). These
ﬁndings are in agreement with previous studies (20). Expres-
sion of VAPB had no signiﬁcant effect on mitochondrial trans-
port. However, expression of VAPBP56S induced a signiﬁcant
decrease in total mitochondrial motility and this was due to
a selective reduction in the number of anterograde moving
mitochondria (Fig. 1).
VAPBP56S decreases the frequency, velocity and
persistence of anterograde mitochondrial movement
To analyze the features underlying the anterograde axonal
transport defect in VAPBP56S-expressing neurons, we deter-
mined the positions of all mitochondria at each time point in
Figure 1. VAPBP56S disrupts anterograde axonal transport of mitochondria. Mitochondrial transport was recorded in neurons co-transfected with DsRed-Mito
and either EGFP (CTRL), EGFP-VAPB (VAPB) or EGFP-VAPBP56S (VAPBP56S) as indicated. (A) Representative kymographs show axonal transport of
mitochondria in EGFP, VAPB or VAPBP56S transfected neurons. (B) The percentages of motile, anterograde and retrograde moving mitochondria are
shown. Expression of VAPB had no effect on mitochondrial transport. In contrast, VAPBP56S reduced mitochondrial transport and this was due to a selective
inhibition of anterograde but not retrograde transport. Statistical signiﬁcance was determined by one-way ANOVA followed by Tukey’s post hoc test. n ¼ 11–14
cells; error bars are SEM. ∗∗P , 0.01; ∗∗∗P , 0.001.
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lated the frequency of anterograde and retrograde movement
events, the duration of stationary periods between movements,
the velocities of movement and the persistence of unidirec-
tional continuous movements. The transport frequency is
an indicator of the regulation of mitochondrial transport
(activation versus inactivation) and the persistence is an
indicator of motor processivity. We applied a velocity
threshold of 0.3 mm/s between successive time points to
deﬁne movement events. This threshold was set to only
include microtubule-based movements, since the reported vel-
ocity of actin-based transport of mitochondria is well below
0.3 mm/s (46).
The overall (anterograde and retrograde combined), antero-
grade and retrograde frequencies of movement events were
not signiﬁcantly different between control EGFP and VAPB
transfected neurons (Table 1). In contrast, expression of
VAPBP56S reduced the overall mitochondrial transport activ-
ity by  50%, and this was caused by a selective inhibition to
anterograde but not retrograde transport activity (Table 1).
This reduction in the frequency of anterograde movement
events in VAPBP56S-expressing cells was accompanied by
a signiﬁcant increase in the amount of time that mitochondria
spent pausing (Table 2). Similar analyses revealed that com-
pared with control EGFP and VAPB transfected neurons,
VAPBP56S signiﬁcantly reduced the velocity and persistence
of anterograde but not retrograde mitochondrial movement
(Tables 3 and 4). Thus, the disruption to anterograde mito-
chondrial transport induced by VAPBP56S is a consequence
of reductions in the frequency, velocity and persistence of
anterograde mitochondrial movements.
VAPBP56S decreases the amount of tubulin
but not kinesin-1 associated with Miro1
The microtubule molecular motor kinesin-1 drives most an-
terograde axonal transport of mitochondria, and attachment
of kinesin-1 to mitochondria involves the outer mitochondrial
protein Miro1 and the adaptor protein TRAK1 (2,7–15). Two
known routes whereby anterograde transport of mitochondria
by kinesin-1 can be disrupted involve release of kinesin-1
from Miro1 or release of mitochondria containing the Miro1/
TRAK1/kinesin-1 complex from microtubules (8,19). We
therefore monitored the effect of VAPB and VAPBP56S ex-
pression on the amounts of kinesin-1 and tubulin that were
associated with Miro1 in immunoprecipitation experiments.
To do so, HEK293 cells were co-transfected with myc-tagged
Miro1 (myc-Miro) and hemagglutinin-tagged TRAK1
(HA-TRAK1), and either control vector, VAPB or
VAPBP56S, and myc-Miro1 immunoprecipitated using the
myc-tag. The amounts of co-immunoprecipitating endogenous
kinesin-1 and a-tubulin were then detected by immunoblot-
ting. Others have used similar immunoprecipitation assays to
investigate how alterations to signaling pathways inﬂuence
binding of kinesin-1 motor complexes to tubulin and axonal
transport of mitochondria (47). Likewise, since the Miro1/
TRAK/kinesin-1 complex is highly conserved in different
organisms and cell types, others have used HEK293 cells to
dissect the mechanisms that control the association of Miro1
with kinesin-1 and tubulin (8). Expression of VAPB or
VAPBP56S did not alter the amounts of kinesin-1 that were
associated with myc-Miro1 in these experiments (Fig. 2).
Rather, expression of VAPBP56S but not VAPB reduced the
amounts of tubulin associated with myc-Miro1 (Fig. 2). This
reduction was observed when the amounts of tubulin were nor-
malized to the amounts of both immunoprecipitated Miro1 and
co-immunoprecipitated kinesin-1. The reduction in tubulin as-
sociation with Miro1 was not due to an effect of VAPBP56S
on TRAK1 because the levels of TRAK1 found in Miro1
immunoprecipitates were unaffected by VAPBP56S (Fig. 2).
Thus, expression of VAPBP56S does not alter the amounts
of kinesin-1 or TRAK1 that are associated with Miro1, but
rather reduces the amount of tubulin that is associated with
the Miro1/TRAK1/kinesin-1 complex.
VAPBP56S increases resting cytosolic Ca
21 levels
Elevation of [Ca
2+]c disrupts anterograde axonal transport of
mitochondria (8,11,16–19). Ca
2+-mediated disruption to
Table 1. VAPBP56S decreases the frequency of anterograde mitochondrial movement events
Motile Anterograde Retrograde
Transfection Frequency (events/
mitochondria/min)
SD P-value Frequency (events/
mitochondria/min)
SD P-value Frequency (events/
mitochondria/min)
SD P-value
Ctrl 4.089 6.28 2.793 5.42 0.784 1.84
VAPB 4.733 6.78 ns 3.234 6.11 ns 1.196 3.00 ns
VAPBP56S 2.031 4.40 ,0.001 0.726 2.64 ,0.001 0.856 2.48 ns
Frequencies of movement were quantiﬁed in DsRed-Mito plus either EGFP (control; Ctrl), EGFP-VAPB (VAPB) or EGFP-VAPBP56S (VAPBP56S)
co-transfected neurons. VAPBP56S induced a signiﬁcant decrease in the frequency of anterograde movements without affecting retrograde movement. Statistical
signiﬁcance was determined by the one-way ANOVA (Kruskal–Wallis) test followed by Dunn’s multiple comparison test; ns, not signiﬁcant.
Table 2. VAPBP56S increases the duration of stationary periods between
mitochondrial movements
Transfection Time (s) SD n (events) P-value
Ctrl 45.95 98.07 2106
VAPB 58.77 129.90 1805 ns
VAPBP56S 79.71 151.20 753 ,0.001
The duration of stationary periods between movements was quantiﬁed for
mitochondria in DsRed-Mito plus either EGFP (control; Ctrl), EGFP-VAPB
(VAPB) or EGFP-VAPBP56S (VAPBP56S) co-transfected neurons. The
duration of stationary periods between movements was signiﬁcantly reduced
by VAPBP56S. Statistical signiﬁcance was determined by the one-way
ANOVA (Kruskal–Wallis) test followed by Dunn’s multiple comparison test;
n ¼ 11–14 cells. ns, not signiﬁcant.
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attached Miro1/TRAK1/kinesin-1 from microtubules (8). Since
VAPBP56S-induced disruption to mitochondrial transport like-
wise involved a reduction in the amount of tubulin associated
with the Miro1/TRAK1/kinesin-1 complex (Fig. 2), we moni-
tored the effect of VAPB and VAPBP56S expression on resting
[Ca
2+]c levels in transfected neurons by Fura2 ratio imaging.
Toensurethatonlyviablecellswereanalyzed,weinducedatran-
sient Ca
2+ i n ﬂ u xb yd e p o l a r i z a t i o nw i t h5 0m M KCl; only cells
that showed a transient increase in [Ca
2+]c were included in
the analyses of resting [Ca
2+]c. Expression of VAPB did not
change resting [Ca
2+]c compared with EGFP-transfected
controlneurons.However,expressionofVAPBP56Ssigniﬁcant-
ly elevated resting [Ca
2+]c (Fig. 3). Thus, VAPBP56S-induced
disruption to anterograde axonal mitochondrial transport is
associated with an increase in resting [Ca
2+]c.
Expression of a Ca
21-insensitive mutant of Miro1 rescues
the effects of VAPBP56S on the association of tubulin
with Miro1 and on mitochondrial motility
These results are consistent with a model in which VAPBP56S
elevates [Ca
2+]c to cause release of mitochondria with asso-
ciated Miro1/TRAK1/kinesin-1 from microtubules to disrupt
axonal transport. Elevation of [Ca
2+]c has been shown to
induce release of mitochondria with associated Miro1/
TRAK1/kinesin-1 from tubulin (8). Since elevated [Ca
2+]c dis-
rupts kinesin-1-based transport of mitochondria via an effect
on the Miro1 EF hands (8,11,19), we enquired whether expres-
sion of a mutant Miro1 in which the EF hands were disrupted
could rescue the effect of VAPBP56S on mitochondria
transport. This mutant Miro1 (Miro1
E208K/E328K) has essential
glutamates in the EF hands altered to lysines to inhibit
binding of Ca
2+ (7). Like wild-type Miro1, Miro1
E208K/E328K
supports axonal transport of mitochondria but rescues the
effect of elevated [Ca
2+]c on mitochondrial transport in a
number of experimental paradigms (8,11,19).
We monitored the effect of Miro1
E208K/E328K on the binding
of TRAK1, kinesin-1 and tubulin in control, VAPB- and
VAPBP56S-expressing cells in immunoprecipitation assays.
HEK293 cells were co-transfected with myc-Miro1
E208K/E328K
and HA-TRAK1, and either control vector, VAPB or VAPBP56S
andtheamountsofendogenouskinesin-1andtubulinassociated
withimmunoprecipitatedmyc-Miro1
E208K/E328Kdetermined by
immunoblotting. The amounts of co-immunoprecipitated
HA-TRAK1,kinesin-1andtubulinwerenotsigniﬁcantlydiffer-
entinanyofthesecells(Fig.4).Thus,whileVAPBP56Sreduces
the amount of tubulin associated with wild-type Miro1 (Fig. 2),
this effect lost in cells expressing Miro1
E208K/E328K.
To determine whether Miro1
E208K/E328K could also rescue
the effect of VAPBP56S on defective anterograde mitochon-
drial axonal transport, we co-transfected neurons with DsRed-
Mito and either VAPB and control vector, VAPBP56S and
control vector, VAPBP56S and Miro1, or VAPBP56S and
Miro1
E208K/E328K and quantiﬁed axonal transport of mitochon-
dria. Compared with VAPB-expressing neurons, VAPBP56S
again reduced anterograde mitochondrial transport, and
this was unaffected by expression of Miro1. However,
co-expression of Miro1
E208K/E328K signiﬁcantly increased
anterograde mitochondrial transport in the
VAPBP56S-expressing cells (Fig. 5). Thus, Miro1
E208K/E328K
rescues defective axonal transport of mitochondria in
VAPBP56S-expressing neurons.
Table 4. VAPBP56S decreases the persistence of anterograde mitochondrial movement
Transfection Anterograde Retrograde
Time (s) SD n (events) P-value Time (s) SD n (events) P-value
Ctrl 8.20 13.46 1928 5.50 5.88 1422
VAPB 9.18 15.08 1624 ns 5.75 6.06 1456 ns
VAPBP56S 5.96 10.04 563 ,0.01 5.74 6.32 664 ns
The persistence of continuous unidirectional movement was quantiﬁed in DsRed-Mito plus either EGFP (control; Ctrl), EGFP-VAPB (VAPB) or
EGFP-VAPBP56S (VAPBP56S) co-transfected neurons. VAPBP56S induced a signiﬁcant decrease in the persistence of anterograde movements, but did not
affect the persistence of retrograde transport. Statistical signiﬁcance was determined by the one-way ANOVA (Kruskal–Wallis) test followed by Dunn’s multiple
comparison test; n ¼ 11–14 cells. ns, not signiﬁcant.
Table 3. VAPBP56S decreases the velocity of anterograde mitochondrial movement
Transfection Anterograde Retrograde
Velocity (mm/s) SD n (events) P-value Velocity (mm/s) SD n (events) P-value
Ctrl 0.78 0.37 5249 0.75 0.40 2592
VAPB 0.80 0.39 4938 ns 0.77 0.41 2765 ns
VAPBP56S 0.68 0.37 1157 ,0.001 0.78 0.42 1255 ns
Velocities were quantiﬁed in DsRed-Mito plus either EGFP (control; Ctrl), EGFP-VAPB (VAPB) or EGFP-VAPBP56S (VAPBP56S) co-transfected neurons.
VAPBP56S induced a signiﬁcant decrease in the velocity of anterograde movements without affecting retrograde velocity. Statistical signiﬁcance was determined
by the one-way ANOVA (Kruskal–Wallis) test followed by Dunn’s multiple comparison test; n ¼ 11–14 cells. ns, not signiﬁcant.
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The molecular mechanisms that underlie motor neuron demise
in ALS are not properly understood but damage to axonal
transport, mitochondria and Ca
2+ homeostasis are all
acknowledged to be early pathological features of the
disease (48,49). Here, we show that VAPBP56S which
causes some dominantly inherited familial forms of motor
neuron disease including ALS type-8 damages axonal trans-
port of mitochondria. Disruption to mitochondrial transport
was directional involving perturbation to anterograde but not
retrograde movement. Mutations in the gene encoding Cu/Zn
superoxide dismutase-1 (SOD1) also cause familial ALS,
and mutant SOD1 likewise perturbs anterograde but not retro-
grade axonal transport of mitochondria (20). Thus, two differ-
ent genetic insults associated with ALS both damage axonal
transport of mitochondria in similar fashions.
This selective effect on anterograde transport suggests that
VAPBP56S may target kinesin-1-based movement; kinesin-1
is the principal anterograde motor for mitochondria (2–7).
Elevation of [Ca
2+]c perturbs mitochondrial transport by
kinesin-1, and this effect is mediated by the outer mitochon-
drial membrane protein Miro1 which acts as a Ca
2+ sensor
(8,11,19). Disruption to Ca
2+ homeostasis is seen in ALS
models (29,50,51), and we show here that VAPBP56S elevates
[Ca
2+]c in transfected neurons. Moreover, we demonstrate
that a Ca
2+-insensitive mutant of Miro1 rescues defective
mitochondrial transport. The precise mechanism by which ele-
vated [Ca
2+]c disrupts anterograde mitochondrial transport by
kinesin-1 are not properly understood, but there is evidence
that it involves release of kinesin-1-bound Miro1 from
tubulin (8). In line with this model, we show that
VAPBP56S reduces the amount of tubulin but not kinesin-1
that is associated with Miro1 and that this effect is rescued
by expression of the Ca
2+-insensitive mutant of Miro1.
Damage to anterograde axonal transport of mitochondria by
VAPBP56S may therefore involve elevation of [Ca
2+]c
which in turn induces release of Miro1 with associated
kinesin-1 from microtubules to halt transport.
VAPB is an integral ER protein and VAPBP56S disrupts
ER structure (26–31). The ER is a store for Ca
2+ and recent
studies have shown that VAPB functions to regulate Ca
2+ ex-
change between ER and mitochondria, and that VAPBP56S is
defective in this process (40). In addition, VAPB is involved in
ER stress and the unfolded protein response (UPR) and there is
evidence that VAPBP56S is also defective in this function al-
though the mechanisms are controversial (29,36–39). In some
reports, expression of VAPB induces UPR and VAPBP56S
inhibits this process (36,37,44). In another, expression of
VAPB and VAPBP56S both inhibit UPR but VAPBP56S is
more potent in this effect (38). Finally, other studies have
shown that VAPB and/or VAPBP56S can induce ER stress
and UPR (29,39). Whatever the precise details, recent
studies have shown that the UPR can inﬂuence Ca
2+ release
from ER stores (52). VAPBP56S perturbation of the ER struc-
ture and UPR may therefore impact on this process.
Figure 2. VAPBP56S reduces the amount of endogenous tubulin but not en-
dogenous kinesin-1 associated with Miro1. (A) HEK293 cells were
co-transfected with either empty vector (EV), empty vector + Myc-Miro1 +
HA-TRAK1, VAPB + Myc-Miro1 + HA-TRAK1 or VAPBP56S +
Myc-Miro1 + HA-TRAK1 as indicated. Miro1 was immunoprecipitated
using the myc-tag and the amounts of co-immunoprecipitating kinesin-1 and
a-tubulin detected by immunoblotting. Samples of the input lysates (Input)
and immunoprecipitates (IP:Myc-Miro1) are shown. (B) Bar graphs show
the relative levels of kinesin-1 and a-tubulin in the immunoprecipitates.
Kinesin-1 signals were normalized to immunoprecipitated myc-Miro1
signal; a-tubulin signals were normalized to both immunoprecipitated
myc-Miro1 and immunoprecipitated kinesin-1 signals as indicated. Values
were converted so that empty vector + Myc-Miro1 + HA-TRAK1 transfec-
tion was assigned a reference value of 1.0. The results shown are from four
independent transfections. Statistical signiﬁcance was determined by
one-way ANOVA followed by Tukey’s post hoc test. n ¼ 4; error bars are
SEM. ∗P , 0.05; ∗∗P , 0.01.
Figure 3. Expression of VAPBP56S increases resting [Ca
2+]c levels in
neurons. Neurons were transfected with either control EGFP vector, EGFP-
VAPB (VAPB) or EGFP-VAPBP56S (P56S) and [Ca
2+]c determined by
Fura2 ratio imaging. Resting [Ca
2+]c was calculated for each individual
neuron as the average resting [Ca
2+]c between 60 and 180 s of measurement
(indicated with box in (A). Values for individual cells were then collated to
generate the bar graph in (B). To ensure that resting [Ca
2+]c was obtained
from viable neurons, we induced a transient inﬂux of Ca
2+ by a 2 min appli-
cation of 50 mM KCl to depolarize the neurons. Only cells that showed a tran-
sient increase in [Ca
2+]c after depolarization were included in the analysis
of resting [Ca
2+]c. Statistical signiﬁcance was determined by one-way
ANOVA (Kruskal–Wallis) followed by Dunn’s multiple comparison test.
n ¼ 10 (CTRL), 14 (VAPB) and 20 (VAPBP56S) cells; error bars are SEM.
∗P , 0.05.
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stress (53), and elevated Ca
2+ levels are also seen in the
mutant SOD1 expressing cells (50). Damage to axonal trans-
port of mitochondria seen in both VAPBP56S and mutant
SOD1 familial forms of ALS may therefore be related to
UPR and defective Ca
2+ handling which in turn perturbs
transport via Miro1.
MATERIALS AND METHODS
Plasmids and mutagenesis
Sequences encoding human VAPB and VAPBP56S were as
described previously (31). Mammalian expression vectors
for VAPB and VAPBP56S were generated by cloning of
VAPB/VAPBP56S sequences into pCI-neo (Promega); amino-
terminal EGFP-tagged versions were generated by cloning
into pEGFP-C1. Expression vectors for myc-tagged Miro1,
HA-tagged TRAK1 and DsRed-Mito were as described previ-
ously (7,20). Glutamates 208 and 328 in the two Miro1 EF
hand domains were mutated to lysine (Miro1
E208K/E328K)
with oligonucleotides 5′-GGTACTCTCAATGATGCTAAA
CTCAACTTCTTTCAGAG-3′ and 5′-CTCTGAAAGAAGTT
GAGTTTAGCATCATTGAGAGTACC-3′, and 5′-GACTG
TGCTTTGTCACCTGATAAGCTTAAAGATTTATTTAAA
G-3′ and 5′-CTTTAAATAAATCTTTAAGCTTATCAGGTG
ACAAAGCACAGTC-3′ using a QuikChange XL site-directed
mutagenesis kit (Stratagene) according to the manufacturer’s
instructions. All constructs were veriﬁed by sequencing.
Antibodies
Mouse anti-myc tag (9B11) was from Cell Signaling Technol-
ogy; rabbit anti-HA antibody was from Sigma and rabbit
anti-a-tubulin was from Abcam. Antibodies to VAPB and
kinesin-1 were as described previously (31,54).
Cell culture and transfection
HEK293 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (PAA Laboratories) containing 4.5 g/l
glucose, 10% fetal bovine serum (Sera Laboratories), 2 mM
L-glutamine (Invitrogen) and 1 mM sodium pyruvate (Sigma)
and were transfected with ExGen500 (Fermentas) according
to the manufacturer’s instructions. Cells were harvested for
analyses 24 h post-transfection.
Cortical neurons were isolated from embryonic day 18 rat
embryos and cultured on glass cover slips coated with
poly-L-lysine in 6- or 12-well plates in neurobasal medium
containing B27 supplement (Invitrogen), 100 IU/ml penicillin,
100 mg/ml streptomycin and 2 mM L-glutamine. Cells were
cultured for 7 days and then transfected using a calcium phos-
phate Profection kit (Promega) as previously described (55).
For studies in HEK293 cells and neurons, all experimental
treatments involved transfection of the same amounts of
DNA; where several plasmids were involved, transfections
were balanced by addition of control vector. For studies on
the effects of Miro1 and Miro1
E208K/E328K on axonal transport,
neurons were transfected with twice the amount of Miro1 or
Miro1
E208K/E328K plasmid compared with DsRed-Mito to
ensure that all cells visualized for mitochondrial transport
expressed Miro1 and this was conﬁrmed by immunostaining
for the myc-tag.
Biochemical puriﬁcations
For immunoprecipitation assays, transfected cells were lysed
in ice-cold immunoprecipitation buffer comprising 50 mM
Tris-citrate, pH 7.4, 150 mM NaCl, 1% Triton X-100, 5 mM
ethylene glycol tetraacetic acid (EGTA), 5 mM ethylenediami-
netetraacetic acid and protease inhibitors (Complete, Roche)
for 1 h. After centrifugation at 100 000g for 40 min at 48C,
the supernatants were precleared with protein G-Sepharose
beads (Sigma) for 30 min at 48C and then incubated with
primary antibody for 16 h at 48C. Antibodies were captured
with protein G-Sepharose beads and following washing with
phosphate-buffered saline supplemented with 0.1% Triton
X-100, bound proteins were eluted by incubation in SDS–
Figure 4. Expression of Ca
2+-insensitive Miro1
E208K/E328K rescues the effect
of VAPBP56S on the association of tubulin with Miro1. (A) HEK293 cells
were co-transfected with either empty vector (EV), empty vector + myc-
Miro1
E208K/E328K (Myc-Miro1KK) + HA-TRAK1, VAPB + myc-
Miro1
E208K/E328K + HA-TRAK1 or VAPBP56S + myc-Miro1
E208K/E328K +
HA-TRAK1 as indicated. Miro1
E208K/E328K was immunoprecipitated using the
myc-tag and the amounts of co-immunoprecipitating kinesin-1 and a-tubulin
detected by immunoblotting. Samples of the input lysates (Input) and immuno-
precipitates (IP:Myc-Miro1KK) are shown. (B) Bar graphs show relative levels
of kinesin-1 and a-tubulin in the immunoprecipitates. Kinesin-1 signals were
normalized to immunoprecipitated myc-Miro1
E208K/E328K signal; a-tubulin
signals were normalized to both immunoprecipitated myc-Miro1
E208K/E328K
and immunoprecipitated kinesin-1 signals as indicated. Values were converted
to so that empty vector + myc-Miro1
E208K/E328K + HA-TRAK1 transfection
was assigned a reference value of 1.0. The results shown are from three inde-
pendent transfections. Statistical signiﬁcance was determined by one-way
ANOVA followed by Tukey’s post hoc test. n ¼ 3; error bars are SEM.
1984 Human Molecular Genetics, 2012, Vol. 21, No. 9PAGE sample buffer and heating at 958C. Samples were then
analysed by immunoblotting.
SDS–PAGE and immunoblotting
Samples were separated on 10% (w/v) acrylamide gels, trans-
ferred to Protran nitrocellulose membranes (Whatman) using a
Transblot system (BioRad) and, following blocking with
Tris–HCl buffered saline (TBS) containing 5% milk powder
and 0.1% Tween-20 for 1 h at room temperature, the mem-
branes were probed with primary antibodies in blocking
buffer for 1 h at room temperature. Following washing with
TBS containing 0.1% Tween-20, the blots were further
probed with horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit Igs and developed using an enhanced
chemiluminescence system (GE Healthcare). Signals on
immunoblots were quantiﬁed using ImageJ (National Insti-
tutes of Health) after scanning with an Epson Precision
V700 Photo scanner essentially as described in our previous
studies (43,56,57). To ensure the signals obtained were
within the linear range, the mean background-corrected
optical density (OD) of each signal was interpolated for an
OD calibration curve created using a calibrated OD step
tablet (Kodak). Only ﬁlm exposures that gave OD signals
within the linear range of the OD calibration curve were
used for statistical analyses. For quantiﬁcation of signals of
kinesin-1 bound to Miro1 in the immunoprecipitation assays,
signals for co-immunoprecipitating kinesin-1 were normalized
to immunoprecipitated Miro1 signal. For quantiﬁcation of
signals of a-tubulin bound to Miro1 in the immunoprecipita-
tion assays, signals for co-immunoprecipitating a-tubulin
were normalized to both immunoprecipitated Miro1 signal
and co-immunoprecipitated kinesin-1 signal.
Microscopy and image analyses
Live microscopy of mitochondrial axonal transport was per-
formed with an Axiovert S100 microscope (Zeiss) equipped
with a Lambda LS Xenon-Arc light source (Sutter Instrument
Company, Novato, CA, USA), an EGFP/DsRed ﬁlterset
(Chroma Technology Corp., Rockingham, VT, USA), 40×
EC Plan-Neoﬂuar 1.3 N.A. objective (Zeiss), Lambda 10-3
ﬁlter wheel (Sutter Instrument Co.) and a Photometrics
Cascade-II 512B High Speed EMCCD camera (Photometrics,
Tuscon, AZ, USA). 36–48 h post-transfection, neurons on
cover slips were transferred to a custom observation
chamber mounted on the stage of the microscope. The cells
were maintained at 378C using an objective heater (Tempcon-
trol 37-2, Zeiss) and ‘The Box’ Microscope Temperature
Control System (Life Imaging Systems). Mitochondrial move-
ments were recorded for 10 min with 3 s time-lapse interval
using Metamorph software (Molecular Devices).
Image analysis was performed with ImageJ developed by
Wayne Rasband (NIH, Bethesda, MD, USA; http://rsb.info.
nih.gov/ij/) extended with custom plug-ins, or Metamorph.
Further calculations and statistical analysis were performed
using Excel (Microsoft Corporation, Redmond, WA, USA),
and Prism software (GraphPad Software Inc., San Diego,
CA, USA).
Calculations of mitochondrial transport parameters were as
described before (20) except that overall transport of mito-
chondria in Figures 1 and 5 was analyzed from kymographs
using the SlopeToVelocity plugin described previously (58).
Brieﬂy, this plugin calculates the velocity by measuring the
distance between the position of individual mitochondria at
the start and end of time-lapse recordings and dividing by
the time elapsed. This yields an overall velocity of transport
Figure 5. VAPBP56S-induced defective anterograde mitochondrial transport is rescued by expression of Ca
2+-insensitive Miro1
E208K/E328K. Neurons were
co-transfected with DsRed-Mito and either EGFP-VAPB, EGFP-VAPBP56S, EGFP-VAPBP56S + Miro1 or EGFP-VAPBP56S + Miro1
E208K/E328K. Transfec-
tions were balanced with empty vector so that all treatments received the same total amounts of DNA. (A) The proportion of anterograde moving mitochondria.
Expression of EGFP-VAPBP56S (P56S) reduced anterograde mitochondrial transport and this was rescued by expression of Miro1
E208K/E328K (MiroKK) but not
wild-type Miro1. Statistical signiﬁcance was determined by one-way ANOVA followed by Tukey’s post hoc test. n ¼ 15–17; error bars are SEM; ∗P , 0.05,
∗∗P , 0.01; ∗∗∗P , 0.001, ns not signiﬁcant. (B) Representative kymographs of mitochondrial movement in neurons co-transfected with EGFP-VAPB (VAPB),
EGFP-VAPBP56S (VAPBP56S), EGFP-VAPBP56S + Miro1 (VAPBP56S + Miro1) or EGFP-VAPBP56S + Miro1
E208K/E328K (VAPBP56S + Miro1KK) as
indicated.
Human Molecular Genetics, 2012, Vol. 21, No. 9 1985that includes anterograde and retrograde movements and
stationary periods. Mitochondria were subsequently classiﬁed
as motile (velocity.0.1 mm/s) or stationary (velocity≤0.1
mm/s).
Calcium measurements
To measure [Ca
2+]c, neurons were loaded with 5 mM Fura2/
AM (Calbiochem) in external solution (145 mM NaCl, 2 mM
KCl, 5 mM NaHCO3,1 m M MgCl2, 2.5 mM CaCl2,1 0 m M
glucose, 10 mM HEPES pH 7.0) for 20 min at 378C followed
by washing in external solution for 20 min at 378C. Fura2/
AM sequential 340 nm and 380 nm excitation images were
recorded in time-lapse mode (1 s interval) at 378C using Meta-
Fluor software (Molecular Dynamics) on an Axiovert 200M
microscope (Zeiss) equipped with a Polychrome V light
source (Till Photonics), Fura2 ﬁlterset (Chroma Technology
Corp.), 40× 1.3NA Fluar objective (Zeiss), Lambda 10-2
ﬁlter wheel (Sutter Instrument Co.) and a Photometrics Cool-
Snap HQ2 camera (Photometrics). Neurons were kept at 378C
on the microscope in a Ludin imaging chamber (Life Imaging
Systems, Basel, Switzerland) using an objective heater (Temp-
control 37, Zeiss) and ‘The Box’ Microscope Temperature
Control System (Life Imaging Systems). During experiments,
neurons were perfused continuously with external solution
(0.5 ml/min) using an Ismatec REGLO peristaltic pump
(IDEX Corporation, Glattbrugg, Switzerland). To invoke
Ca
2+ inﬂux, 50 mM KCl was applied in external solution
(NaCl was replaced with equimolar amounts of KCl) for
2 min. [Ca
2+]c levels were calculated from the ratio of ﬂuor-
escent signals at excitation 340 and 380 nm, and calibrated by
sequential addition of saturating CaCl2 (20 mM) and EGTA
(20 mM) in external solution after incubation with 10 mM
A23187 Ca
2+-ionophore (Sigma) and then translated to nano-
molar using the Grynkiewicz formula (59). Resting [Ca
2+]c
was determined as the average ratio value between 60 and
180 s of recording.
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